These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. Kutuk T; Appel H; Avendano MC; Albrecht F; Kaywin P; Ramos S; Suarez-Murias ME; Mehta MP; Kotecha R Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454925 [TBL] [Abstract][Full Text] [Related]
11. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867 [TBL] [Abstract][Full Text] [Related]
12. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. Cameron RB; Hou D J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177 [TBL] [Abstract][Full Text] [Related]
13. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells. Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262 [TBL] [Abstract][Full Text] [Related]
14. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675 [TBL] [Abstract][Full Text] [Related]
17. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma. Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E Elife; 2023 Nov; 12():. PubMed ID: 37955637 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332 [TBL] [Abstract][Full Text] [Related]
19. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth. Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908 [TBL] [Abstract][Full Text] [Related]
20. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Nowak AK; Cook AM; McDonnell AM; Millward MJ; Creaney J; Francis RJ; Hasani A; Segal A; Musk AW; Turlach BA; McCoy MJ; Robinson BW; Lake RA Ann Oncol; 2015 Dec; 26(12):2483-90. PubMed ID: 26386124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]